Developing Thermally Stable Dry Powder Vaccine Platforms Via Spray Drying Tailored for Inhalation Delivery **

疫苗开发方面的创新通过寻求新的和改进的生物制剂，并通过改变配方和制造重新设想新的递送路线，极大地有利于公共卫生。拟议的研究将推动一个跨学科科学家团队在设计针对结核病和流感感染的新型热稳定疫苗平台**方面取得的最新进展，其中温度敏感的**生物制剂将通过封装在合适的载体中来稳定，从而消除了在储存和运输中**昂贵且通常不可用的制冷设备的必要性。拟议的项目汇集了化学工程和生物医学专业知识，以了解和实施工业相关的干燥技术，这些技术将**生产耐热干粉疫苗，以保持其原始液体形式的免疫增强效力**，但现在可以在室温下储存3个月而不失去活性**，而液体效力损失在不到一周的时间内发生。在优化条件下对这些疫苗粉末进行喷雾干燥，可使产品通过吸入输送到肺部，提高其对结核病和流感等肺源性感染的有效性，同时避免了在给药前在液体介质中重新配制干燥疫苗的复杂物流。这项研究将产生耐热干粉结核病和流感疫苗的最佳范例，将它们的物理和生物特性与人类呼吸系统中颗粒形成和颗粒空气动力学的工程原理联系起来。新知识将转移给适当的**制药专家，以造福加拿大公共卫生。

Innovations in vaccine development greatly benefit public health, by pursuing new and**improved biologics, and re-envisioning new delivery routes though changes in their**formulation and manufacture. The proposed research will advance recent progress made by**an interdisciplinary team of scientists in designing new thermally stable vaccine platforms**targeted against tuberculosis and influenza infection, where the temperature sensitive**biologics will be stabilized by encapsulation in suitable carriers, thereby removing the**necessity for costly and often unavailable refrigeration equipment in their storage and**transport. The proposed project brings together chemical engineering and biomedical**expertise to understand and implement industrially relevant drying techniques that will**produce thermostable dry powder vaccines retaining their immune-boosting potency as seen**in their original liquid form, yet now can be stored at room temperature for 3 months without**loss in activity whereas liquid losses in potency occur in less than 1 week. Spray-drying these**vaccine powders under optimized conditions results in a product designed for delivery to the**lung by inhalation, boosting their effectiveness against lung-borne infections like tuberculosis**and influenza, while avoiding the complex logistics of re-constituting dried vaccines in liquid**media prior to administration. The research will produce optimal examples of thermostable**dry powder tuberculosis and influenza vaccines, relating their physical and biological**properties to engineering principles on particle formation and particle aerodynamics in the**human respiratory system. The new knowledge will be transferred to appropriate**pharmaceutical experts for the benefit of Canadas public health.